Ondansetron FDA Link Generic

A competitive serotonin type 3 receptor antagonist. It is effective in the treatment of nausea and vomiting caused by cytotoxic chemotherapy drugs, including cisplatin, and has reported anxiolytic and neuroleptic properties.

Also Known As:

Zofran; SN 307; GR-38032F; GR38032F; Ondansetron Hydrochloride; Ondansetron Monohydrochloride; Ondansetron Monohydrochloride Dihydrate; Ondansetron, (+,-)-Isomer; Ondansetron, (R)-Isomer; Ondansetron, (S)-Isomer; SN-307; Dihydrate, Ondansetron Monohydrochloride; GR 38032F; Hydrochloride, Ondansetron; Monohydrochloride Dihydrate, Ondansetron; Monohydrochloride, Ondansetron; ODT, Zofran; SN307; 4H-Carbazol-4-one, 1,2,3,9- tetrahydro- 9- methyl- 3- ((2- methyl- 1H- imidazol- 1- yl)methyl)- ; Zofran ODT

Pharmalogical Action Categories:

Antiemetics
Antipruritics

Heterocyclic Compounds: 207
- 1-Ring Heterocyclic Compounds
  - Azoles: 2199
    - Imidazoles: 152
      - Ondansetron: 2613
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Indoles: 205
      - Carbazoles: 33
        Ondansetron: 2613
  - 3-Ring Heterocyclic Compounds
    - Carbazoles: 33
      - Ondansetron: 2613

Cristina Armero Selected Research

Cristina Armero Research Topics

Disease

Drug/Important Bio-Agent (IBA)

Therapy/Procedure